연구성과로 돌아가기
2024 연구자 정보 (48 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Kolenovska, Radka (Kolenovska, R) |
Vaccitech, Harwell, Oxon, South Korea |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Kopycinski, Jakub (Kopycinski, J) |
Vaccitech, Harwell, Oxon, South Korea |
|
|
[JCR상위 1.7] Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | tom.evans@barinthusbio.com; | ||
|
Kudo, Masatoshi (Kudo, M) |
Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan |
AAA-9744-2019 Kudo, Masatoshi |
|
[JCR상위 1.7] EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. [JCR상위 1.7] mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma |
SCIE | 1.7 |
ONCOLOGY GASTROENTEROLOGY & HEPATOLOGY |
bsangro@unav.es; | ||
|
Kwon, So Young (Kwon, SY) |
Konkuk Univ, Med Ctr, Seoul, South Korea |
|
|
[JCR상위 1.7] Multinational randomized trial to investigate the efficacy of tenofovir alafenamide in reducing adverse clinical events in chronic hepatitis B patients who are beyond treatment indications by current guidelines (ATTENTION trial): first interim analysis | SCIE | 1.7 | GASTROENTEROLOGY & HEPATOLOGY | limys@amc.seoul.kr; | ||
|
Lee, Hyun-Jung (Lee, HJ) |
Kyungpook Natl Univ Hosp, Dept Obstet & Gynecol, Daegu, South Korea |
|
|
[JCR상위 1.7] Evaluation of malignant potential based on infection with high-risk human papillomaviruses 16, 52, and 58 in the uterine cervix [JCR상위 1.7] Magnetic resonance texture analysis for predicting histologic tumor type in endometrial cancer |
SCIE | 1.7 | ONCOLOGY | |||
|
Lee, In Kyu (Lee, IK) |
|
|
[JCR상위 1.7] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial | SCIE | 1.7 | ONCOLOGY | ||||
|
Lee, Inhee (Lee, I) |
제1저자 | Kyungpook Natl Univ Hosp, Daegu, South Korea |
|
|
[JCR상위 1.7] Preoperative and postoperative platelet-lymphocyte ratio as a prognostic marker for patients with soft tissue sarcoma treated with curative resection | SCIE | 1.7 | ONCOLOGY | ||
|
Lee, Janghee (Lee, J) |
제1저자 |
|
|
[JCR상위 1.7] Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06) | SCIE | 1.7 | ONCOLOGY | |||
|
Lee, Jeeyeon (Lee, J) |
제1저자 |
Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Sch Med, Dept Surg, Daegu, South Korea Kyungpook Natl Univ, Sch Med, Dept Surg, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Dept Surg, Hoguk Ro 807, Daegu 41404, South Korea Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Breast & Thyroid Surg, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Hoguk Ro 807, Daegu 41404, South Korea Kyungpook Natl Univ, Chilgok Hosp, Div Breast & Thyroid Surg, Dept Surg, 807 Hoguk Ro, Daegu 41404, South Korea Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Daegu, South Korea Northwestern Univ, Feinberg Sch Med, Chicago, IL USA Kyungpook Natl Univ, Sch Med, Daegu, South Korea Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Surg, Daegu 40414, South Korea |
Q-3108-2018 KVY-9550-2024 AER-7002-2022 LEE, JIN Lee, Jong-Mok Lee, Jongseung |
0000-0003-1826-1690 Lee, Jeeyeon |
[JCR상위 1.7] Ten-year outcomes of targeted axillary surgery after neoadjuvant chemotherapy in breast cancer [JCR상위 36.0] Feasibility of an indocyanine green-hyaluronic acid mixture (LuminoMark™) for targeting suspicious axillary lymph nodes in patients with breast cancer [JCR상위 18.7] A Comparison Study of Nipple-Areolar Complex Measurement: Light Detection and Ranging (LiDAR) Camera Versus Photometry [JCR상위 91.3] Primary Invasive Ductal Carcinoma Arising in Axillary Accessory Breast: A Case Report [JCR상위 1.7] Uncovering of NRAGE/JNK and PI3K/AKT pathways through serial WGS of patients with breast cancer [JCR상위 8.2] Robot-Assisted Latissimus Dorsi Flap Harvest for Partial Breast Reconstruction: Comparison With Endoscopic and Conventional Approaches [JCR상위 70.5] Postoperative Scar Management Using Laser Therapy for Breast Reconstruction With Latissimus Dorsi Flap [JCR상위 11.0] Importance of multimodal resident education curriculum for general surgeons: perspectives of trainers and trainees [JCR상위 44.0] Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer [JCR상위 65.0] Long non-coding RNA SOX2OT in tamoxifen-resistant breast cancer [JCR상위 49.8] Usefulness of cordless ultrasonic cutting energy devices in endoscopic nipple-sparing mastectomy: a retrospective study [JCR상위 1.7] Enhanced dacarbazine efficacy in advanced melanoma patients previously treated with immune checkpoint inhibitors in Korea [JCR상위 1.7] Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. [JCR상위 46.8] Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments [JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study [JCR상위 61.2] Survival Outcomes Based on Axillary Surgery in Ductal Carcinoma In Situ: A Nationwide Study From the Korean Breast Cancer Society [JCR상위 37.6] Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy [JCR상위 61.2] Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial [JCR상위 0.2] Minimal Access vs Conventional Nipple-Sparing Mastectomy |
SCIE ESCI SSCI;SCIE |
0.2 |
ONCOLOGY SURGERY RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING MEDICINE, RESEARCH & EXPERIMENTAL EDUCATION & EDUCATIONAL RESEARCH;EDUCATION, SCIENTIFIC DISCIPLINES CELL BIOLOGY ONCOLOGY;RESPIRATORY SYSTEM |
phy123@knu.ac.kr; daniel302@naver.com;rjyflying@naver.com;lambyang@knu.ac.kr;leejspo@knu.ac.kr; mamrad@knu.ac.kr; lambyang@knu.ac.kr; jjh01@knu.ac.kr; yschae@knu.ac.kr; j.lee@knu.ac.kr; ychae@nm.org; sun2729@naver.com; YCHAE@nm.org; likeicetea@hanmail.net;hblee.md@snu.ac.kr; imgenius@yuhs.ac;j.lee@knu.ac.kr; |
|
|
Lee, Jong Seok (Lee, JS) |
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea |
|
|
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Lee, Kyung Ha (Lee, KH) |
|
|
[JCR상위 1.7] Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial | SCIE | 1.7 | ONCOLOGY | ||||
|
Lee, Nam Su (Lee, NS) |
Soon Chun Hyang Univ Hosp, Dept Internal Med, Seoul, South Korea |
|
|
[JCR상위 1.7] Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY | SCIE | 1.7 | ONCOLOGY | ykkang@amc.seoul.kr; | ||
|
Lee, Salie (Lee, S) |
|
|
[JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY | ||||
|
Lee, Seung-Mi (Lee, SM) |
제1저자 | Kyungpook Natl Univ Hosp, Dept Obstet & Gynecol, Daegu, South Korea |
|
|
[JCR상위 1.7] Evaluation of malignant potential based on infection with high-risk human papillomaviruses 16, 52, and 58 in the uterine cervix [JCR상위 1.7] Magnetic resonance texture analysis for predicting histologic tumor type in endometrial cancer [JCR상위 1.7] Analysis of prognostic factors in uterine cervical malignancy treated with concurrent chemoradiation therapy: A retrospective study in two centers in Korea. |
SCIE | 1.7 | ONCOLOGY | ||
|
Lee, Seyoung (Lee, S) |
|
|
[JCR상위 1.7] An interpretable AI-derived radiology signature to identify patients at risk of progression on the PACIFIC regimen for unresectable non-small cell lung cancer [JCR상위 1.7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC) [JCR상위 1.7] Pre-treatment CT radiomics for predicting immunotherapy response in non-small cell lung cancer(NSCLC): RECIST vs. irRECIST criteria [JCR상위 1.7] Harmonization radiomics model to predict immune checkpoint inhibitor-related pneumonitis (CIP) in patients with non-small cell lung cancer (NSCLC) [JCR상위 1.7] AI-based radiomics model for predicting immune checkpoint inhibitor-related pneumonitis (CIP) in patients with advanced NSCLC: An external validation study |
SCIE | 1.7 | ONCOLOGY |
페이지 이동: